期刊文献+

我国生物制品的病毒安全性管理现状及检验检疫监管的探讨 被引量:2

The viral safety management status of biological products and discussion on the inspection and quarantine supervision
原文传递
导出
摘要 目的分析检验检疫部门对出入境生物制品病毒安全性管理需要关注的几个方面。方法通过分析生物制品病毒安全性控制的迫切性和我国生物产品的病毒安全性管理现状,探讨检验检疫部门对出入境生物制品病毒安全性管理需要关注的重点。结果需完善生物技术产品病毒安全性相关法规文件和技术指导原则和病毒安全性技术检测体系。结论检验检疫部门需加强出入境生物制品的病毒安全性检测能力、加强合作,提升检验检疫部门出入境生物制品病毒安全性监测能力。 Objective Analyzing the viral safety management of biological products of entry-exit inspection and quarantine department need attention. Methods Through analyzing the urgency of virus safety control and management situation of biological products, we discuss the focus of concern viral safety management of entry-exit biological products concern. Results We need to improve viral safety related regulatory documents and technical guidelines of biotechnology products and viral safety technology inspection system immediately. Conclusion Entry-exit inspection and quarantine department requires developing of entry and exit biologics viral safety testing capability, strengthen cooperation, enhancing the entry-exit inspection and quarantine departments biologics viral safety monitoring capabilities.
出处 《中国国境卫生检疫杂志》 CAS 2015年第6期442-444,448,共4页 Chinese Journal of Frontier Health and Quarantine
基金 江苏检验检疫局立项课题(2015KJ37)
关键词 生物制品 病毒安全性 现状 Biological products Viral safety Status
  • 相关文献

参考文献6

二级参考文献38

  • 1章金刚.生物技术产品的病毒安全性[J].中国医药生物技术,2007,2(2):81-84. 被引量:7
  • 2孔艳,董关木.逆转录病毒及对生物制品污染的安全问题[J].微生物学免疫学进展,2011,39(1):80-82. 被引量:1
  • 3马玉楠.牛源性产品的生物安全性要求[J].中国生化药物杂志,2005,26(1). 被引量:2
  • 4[4]Zhang JG.Viral safety for animal-derived products//British Council.China-UK Workshop on food safety,Zhengzhou,2006.Beijing:British Council Beijing Branch,2006:27-28.
  • 5[7]WHO.Requirements for the use of animal cells as in vitro substrates for the production of biologicals.WHO Technical Report Series,No.927,2005[EB/OL].[2007-03-23].http://www.who.int/biologicals/areas/blood_products/ANNEX%204%20Animal%20cellsP135-137.pdf.
  • 6[8]Committee for Proprietary Medicinal Products NOTE for guidance on virus validation studies:the design,contribution and interpretation of studies validating the inactivation and removal of viruses[EB/OL].(1996-02-14)[2007-03-23].http://www.emea.eu.int/pdfs/human/bwp/026895en.pdf.
  • 7[9]Committee for Proprietary Medicinal Products.NOTE for guidance on plasma-derived medical products[EB/OL].(2001-01-25)[2007-03-24].http://www.emea.eu.int/pdfs/human/bwp/026995en.pdf.
  • 8[10]ICH.Note for guidance on quality of biotechnological products:viral safety evaluation of biotechnology products derived from cell lines of human or animal origin[EB/OL].(2001-01-25)[2007-03-24].http://www.tga.gov.au/docs/pdf/euguide/ich/29595en.pdf.
  • 9[11]U.S.Department of Health and Human Services,Food and Drug Administration,Center for Biologics Evaluation and Research.Characterization and qualification of cell substrates and other biological starting materials used in the production of viral vaccines for the prevention and treatment of infectious diseases[EB/OL].(2006-09-28)[2007-03-19].http://www.fda.gov/cber/gdlns/vaccsub strates.pdf.
  • 10[12]Center for Biologics Evaluation and Research,Food and Drug Administration.Points to consider in the characterization of cell lines used to produce biologicals[EB/OL].(1993-06-12)[2007-03-20].http://www.fda.gov/cber/gdlns/ptccell.pdf.

共引文献19

同被引文献8

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部